NO974076L - Reduksjon av infarktvolum ved å anvende citicolin - Google Patents

Reduksjon av infarktvolum ved å anvende citicolin

Info

Publication number
NO974076L
NO974076L NO974076A NO974076A NO974076L NO 974076 L NO974076 L NO 974076L NO 974076 A NO974076 A NO 974076A NO 974076 A NO974076 A NO 974076A NO 974076 L NO974076 L NO 974076L
Authority
NO
Norway
Prior art keywords
citicoline
reduction
treatment
infarct volume
infarction
Prior art date
Application number
NO974076A
Other languages
English (en)
Other versions
NO974076D0 (no
NO313538B1 (no
Inventor
Bobby Winston Sandage
Marc Fisher
Kenneth W Locke
Original Assignee
Interneuron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974076(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/603,102 external-priority patent/US5872108A/en
Priority claimed from US08/609,448 external-priority patent/US5827832A/en
Application filed by Interneuron Pharma filed Critical Interneuron Pharma
Publication of NO974076D0 publication Critical patent/NO974076D0/no
Publication of NO974076L publication Critical patent/NO974076L/no
Publication of NO313538B1 publication Critical patent/NO313538B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19974076A 1995-03-06 1997-09-04 Anvendelse av citicolin samt farmasöytisk preparat NO313538B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39926295A 1995-03-06 1995-03-06
US08/603,102 US5872108A (en) 1995-03-06 1996-02-20 Reduction of infarct volume using citicoline
US08/609,448 US5827832A (en) 1995-03-06 1996-03-01 Method of protecting brain tissue from cerebral infarction subsequent to ischemia
PCT/US1996/003159 WO1996027380A1 (en) 1995-03-06 1996-03-06 Reduction of infarct volume using citicoline

Publications (3)

Publication Number Publication Date
NO974076D0 NO974076D0 (no) 1997-09-04
NO974076L true NO974076L (no) 1997-10-28
NO313538B1 NO313538B1 (no) 2002-10-21

Family

ID=27410335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974076A NO313538B1 (no) 1995-03-06 1997-09-04 Anvendelse av citicolin samt farmasöytisk preparat

Country Status (14)

Country Link
EP (1) EP0813416B1 (no)
JP (1) JPH11511732A (no)
CN (2) CN1126546C (no)
AT (1) ATE296103T1 (no)
AU (1) AU5304796A (no)
BR (1) BR9607206A (no)
CA (1) CA2213000A1 (no)
DE (1) DE69634773T2 (no)
ES (1) ES2244968T3 (no)
MX (1) MX9706808A (no)
NO (1) NO313538B1 (no)
PL (1) PL185124B1 (no)
PT (1) PT813416E (no)
WO (1) WO1996027380A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
AU1944799A (en) * 1997-12-24 1999-07-19 Interneuron Pharmaceuticals, Inc. Hyperhydrated citicoline, process and use
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
PL370371A1 (en) 2001-10-15 2005-05-16 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
RU2595857C2 (ru) 2012-05-31 2016-08-27 Кинки Юниверсити Средство для профилактического и/или терапевтического лечения периферической нейропатической боли, вызываемой противораковым средством
ES2906614T3 (es) * 2012-10-30 2022-04-19 Kyowa Hakko Bio Co Ltd Agente para evitar o mejorar el deterioro de la función cerebral
CN105769882B (zh) * 2016-03-14 2019-02-22 北京赛德维康医药研究院 一种抑制血栓形成的药物组合物及其用途
US10709710B2 (en) 2017-05-09 2020-07-14 Hospital Clinic De Barcelona Composition comprising uric acid for the treatment treated with mechanical thrombectomy
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
IT1207106B (it) * 1980-04-18 1989-05-17 Made Italiana Srl Ora Searle I Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale

Also Published As

Publication number Publication date
NO974076D0 (no) 1997-09-04
EP0813416A1 (en) 1997-12-29
ES2244968T3 (es) 2005-12-16
DE69634773T2 (de) 2006-05-04
DE69634773D1 (de) 2005-06-30
CN1126546C (zh) 2003-11-05
EP0813416B1 (en) 2005-05-25
CN1181015A (zh) 1998-05-06
MX9706808A (es) 1998-08-30
JPH11511732A (ja) 1999-10-12
BR9607206A (pt) 1997-11-11
CA2213000A1 (en) 1996-09-12
CN1488353A (zh) 2004-04-14
PT813416E (pt) 2005-10-31
ATE296103T1 (de) 2005-06-15
AU5304796A (en) 1996-09-23
NO313538B1 (no) 2002-10-21
EP0813416A4 (en) 2000-11-15
PL185124B1 (pl) 2003-02-28
PL322061A1 (en) 1998-01-05
WO1996027380A1 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
NO974076D0 (no) Reduksjon av infarktvolum ved å anvende citicolin
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
GR3007251T3 (no)
EP0703785B8 (en) Methods for treating muscle diseases and disorders
HK1007102A1 (en) Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
EP0945135A3 (en) Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
BG97068A (bg) Фармацевтичен състав и метод за постигане на терапевтичен ефект
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
AU4385399A (en) Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
EP1294375A4 (en) METHOD FOR THE TREATMENT OF SEBORRHOIC DERMATITIS
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
NZ299006A (en) Use of 4-dichlorophenyl tetrahydro N-methyl-1-naphthalenamine (sertraline) for heart attack treatment
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
SE9302333D0 (sv) New compounds
Almeida et al. Effects of a purified scorpion toxin (tityustoxin) on the isolated guinea pig heart
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
MY107336A (en) The process for the preparation of enantiomerically pure thienopyran derivatives.
ES2194907T3 (es) Utilizacion de la espiramicina en desordenes gastro-intestinales debido al h.pylori.
Salmaso et al. Serratia spp. bacteremias in AIDS/ARC patients.
MX9602793A (es) Uso de sertralina para tratar pacientes despues de un infarto de miocardio.
EP0621789A4 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.

Legal Events

Date Code Title Description
MK1K Patent expired